A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Oblimersen (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2008 Status change from in progress to completed as reported by clinicaltrials.gov.
    • 31 May 2008 The expected completion date for this trial was 1 May 2008 as reported by clinicaltrials.gov.
    • 17 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top